These properties make survivin an attractive target for cancer therapies [141].The aim of the study was to investigate the safety, immunological effects and survival of patients with newly diagnosed GBM who received SurVaxM together with adjuvant TMZ after surgery and chemoradiotherapy. The gene discussed is BIRC5; the disease is glioblastoma.